Abstract

The improvement in glucose control in diabetics’ life is the major challenge for those failing oral therapy and refuses to take injections. The RapidMist, a novel Diabetes Management System, can provide better post-prandial glucose control without pain. This system is based on the unique liquid aerosol formulation directed in the mouth. The goal of the study was to evaluate the efficacy of the oral insulin (100 units) in combination with failing oral agents to control post-prandial glucose in Type-2 diabetic patients after standard meal challenges at breakfast, lunch and dinnertime. In a randomized crossover study, 24 Type-2 diabetic patient runs were performed with MiniMed Continuous Glucose Monitoring System (CGMS). Patients received oral insulin (100 units) via the RapidMist device in combination with oral tablets with each daily meal on one day or oral hypoglycemic agents only in another. The table below shows serum glucose changes after the dose of Oralin or oral agents alone, following breakfast, lunch and dinner, at baseline (0 min) and Post Prandial Max (2h).

Oral Insulin taken at meal times was associated with a significantly lower postprandial glucose rise (9% vs 27%, p<0.001) when compared with days which patients received the oral agents alone. Oralin can be used effectively with failing oral agents as an add-on therapy to achieve better control on meal related glucose rise and avoid future diabetic complications.

Introduction | Abstract |
Oral Insulin Spray | Study Goal, Method, Research, Conclusions